Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Beyne-Rauzy

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
European Journal of Nuclear Medicine and Molecular Imaging|July 5, 2015
FDG-PET/CT findings in systemic mastocytosis: a French multicentre studyS Djelbani-Ahmed, M O Chandesris, A Mekinian, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
European Journal of Nuclear Medicine and Molecular Imaging|July 5, 2015
FDG-PET/CT findings in systemic mastocytosis: a French multicentre studyS Djelbani-Ahmed, M O Chandesris, A Mekinian, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 3